JERUSALEM and NEEDHAM, Massachusetts, June 17 Oridion Systems Ltd. - (SWX: ORIDN) Significant findings from numerousmedical research projects demonstrating the clinical benefit of end-tidal CO2(EtCO2) monitoring using Microstream(R) capnography technology, were recentlypresented at medical congresses in the United States and Europe.
During Digestive Disease Week (DDW) in San Diego, California, Dr. Vargo,of the Cleveland Clinic, presented a blinded study that analyzed 122randomized patients and showed that Microstream(R) capnography "significantlyreduces the proportion of patients with hypoxemia, major hypoxemia, apnea andoxygen requirements during ERCP (Endoscopic RetrogradeCholangiopancreatography) and EUS (Endoscopic ultrasound).
Other studies describing the clinical value of Microstream(R) EtCO2monitoring were presented during the European Resuscitation Council (ERC) inGhent, Belgium and the European Society of Anesthesiology (ESA) inCopenhagen, Denmark. At ERC, two oral presentations were given and aCapnography Symposium took place with three distinguished clinicians and theclinical practice manager from London Ambulance Service. The fourpresentations showed the value of capnography in pre-hospital care (trauma,intubations, and ROSC). The Symposium was moderated by Prof. Pierre Carli,President Societe Francaise d'Anesthesie et de Reanimation (French Society ofAnesthesia and Intensive Care).
Two medical presentations given at European Society of Anesthesiademonstrated the importance of capnography for non-intubated and intubatedpatients. In a study on the use of continuous non-invasive arterial CO2estimation in spontaneously breathing patients after craniotomy, Dr. Wolterfrom France showed a good correlation between capnography and arterial bloodgas analysis in sedated patients under regional anesthesia.
"These recent studies continue to confirm that patients are safer whentheir caregivers use Oridion Microstream(R) capnography technology," statedGerry Feldman, President of Oridion Capnography. "The results of these globalresearch projects clearly demonstrate that capnography improves patientsafety and should be included in hospital and pre-hospital ventilatorymonitoring strategies."
Oridion is the global leader of innovative capnography monitoringsolutions helping to improve patient safety, and its Microstream(R)capnography technology has become the standard of care in ventilationmonitoring.
A full list of these medical abstracts can be found on the Oridionwebsite:http://www.oridion.com/global/english/clinical_solutions/overview/research.html.
Oridion Systems Ltd. (www.oridion.com) is a global medical device companyspecializing in patient safety monitoring. The Company operates throughwholly owned subsidiaries in the United States, Europe, and Israel.
Oridion develops proprietary medical devices and patient interfaces,based on its patented Microstream(R) technologies, for the enhancement ofpatient safety through the monitoring of the carbon dioxide (CO2) in apatient's breath. These products provide effective, proven airway managementand are used in various clinical environments, including procedural sedation,pain management, operating rooms, critical care units, post-anesthesia careunits, emergency medical services, transport, alternate care and othersettings where patients' ventilation may be compromised and at risk.
Certain statements made herein that are not historical areforward-looking. The words "estimate" "project" "intend" "expect" "believe"and similar expressions are intended to identify forward-looking statements.These forward-looking statements involve known and unknown risks anduncertainties. Many factors could cause the actual results, performance orachievements of the Company to be materially different from any futureresults, performance or achievements that may be express